Hoth Therapeutics

HOTH

Market cap $16.9M

NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships.

NobleCon is the preeminent showcase of small and microcap companies NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL. To learn more about NobleCon and registration to attend or scheduling a one-on-one meeting with management please visit https://nobleconference.com/ About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life.

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms. Acceptance into the NVIDIA Connect Program provides Hoth Therapeutics with access to a suite of accelerated computing resources, technical guidance, and marketing support, enabling the company to further strengthen its AI-powered research initiatives across its therapeutic pipeline.

Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health. NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and inflammatory diseases, today announced the initiation of a U.S. Department of Veterans Affairs (VA)–backed study evaluating the potential of glial cell line–derived neurotrophic factor (GDNF)as a novel therapy for obesity and fatty liver disease (hepatic steatosis).

>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Planned Next Steps (Near-Term): Complete GLP toxicology and CMC packages; submit IND.

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological, oncological disorders, today announced it has expanded its artificial intelligence (AI) initiative through a new NVIDIA AI Enterprise subscription license to accelerate data-driven drug development, preclinical modeling, and predictive analytics. Under the new entitlement and renewal agreement, Hoth Therapeutics has secured annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research.

Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology programtargeting KIT-driven tumors NEW YORK , Oct. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for dermatological, oncology, and Alzheimer's, today announced that Chief Executive Officer Robb Knie will be presenting at the upcoming BIO-Europe 2025 Conference, taking place November 3–5, 2025, in Vienna, Austria. At the conference, Mr.

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.

NEW YORK , Sept. 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring momentum across its lead clinical programs and corporate strategy.

NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi).